Home MAPK Raf inhibitor - PDGFR inhibitor - VEGFR inhibitor - FLT3 inhibitor - c-Kit inhibitor - FGFR inhibitor - Ferroptosis activator - Autophagy activator - Apoptosis related activator Sorafenib tosylate For research use only.

Sorafenib tosylate

Synonyms: BAY 43-9006 tosylate,NSC-724772 tosylate

Sorafenib tosylate is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.

Sorafenib tosylate Chemical Structure

Sorafenib tosylate Chemical Structure

CAS: 475207-59-1

Selleck's Sorafenib tosylate has been cited by 262 publications

Purity & Quality Control

Batch: Purity: 99.99%
99.99

Products often used together with Sorafenib tosylate

Lenvatinib

Lenvatinib exhibits more potent antitumor activity than sorafenib in immunocompetent mice.

Kimura T, et al. Cancer Sci. 2018 Dec;109(12):3993-4002.

Regorafenib

Sorafenib tosylate and Regorafenib exhibit antitumor activities in preclinical models of hepatocellular carcinoma.

Kissel M, et al. Oncotarget. 2017 Dec 5; 8(63): 107096–107108.

Cisplatin

Sorafenib tosylate and Cisplatin synergistically inhibit tumor growth in situ.

Wang Y, et al. Int J Pharm. 2016 Apr 30;503(1-2):150-62.

Danusertib (PHA-739358)

Sorafenib tosylate and PHA-739358 combination stops tumor growth in mice.

Benten D, et al. Neoplasia. 2009 Sep; 11(9): 934–944.

Paclitaxel

Sorafenib tosylate and Paclitaxel induce anti-angiogenic, anti-tumor, and anti-resorptive effects in experimental breast cancer bone metastases.

Merz M, et al. Eur J Cancer. 2011 Jan;47(2):277-86.

Other Raf Products

Related compound libraries

Choose Selective Raf Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-435 Growth Inhibition Assay 48 h GI50=2 μM 22560627
UACC257 Growth Inhibition Assay 48 h GI50=2 μM 22560627
MCF7 Growth Inhibition Assay 48 h GI50=2.5 μM 22560627
EKVX Growth Inhibition Assay 48 h GI50=2.5 μM 22560627
HT-29 Growth Inhibition Assay 48 h GI50=2.5 μM 22560627
SNB19 Growth Inhibition Assay 48 h GI50=3.2 μM 22560627
OVCAR3 Growth Inhibition Assay 48 h GI50=3.2 μM 22560627
CAKI-1 Growth Inhibition Assay 48 h GI50=3.2 μM 22560627
SW620 Growth Inhibition Assay 48 h GI50=3.2 μM 22560627
TK10 Growth Inhibition Assay 48 h GI50=5 μM 22560627
endothelial precursor cells Function assay Inhibition of endothelial cord area formation in endothelial precursor cells by CD31 cord area detection based phenotypic drug discovery based assay, IC50 = 0.00421 μM. 22409666
Sf9 Function assay Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay, IC50 = 0.0125 μM. 24368209
endothelial precursor cells/ADSC cells Toxicity assay Toxicity in endothelial precursor cells co-cultured with stromal precursor ADSC cells by total nuclei count detection based phenotypic drug discovery based assay, EC50 = 5.46 μM. 22409666
endothelial precursor cells Function assay Inhibition of cell migration in endothelial precursor cells by Oris cell migration kit based phenotypic drug discovery based assay, IC50 = 16.7 μM. 22409666
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
Click to View More Cell Line Experimental Data

Biological Activity

Description Sorafenib tosylate is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Targets
Raf-1 [1]
(Cell-free assay)		 VEGFR2/Flk1 [1]
(Cell-free assay)		 B-Raf [1]
(Cell-free assay)		 B-Raf (V599E) [1]
(Cell-free assay)		 PDGFRβ [1]
(Cell-free assay)		 Click to View More Targets
6 nM 15 nM 22 nM 38 nM 57 nM
In vitro
In vitro

Sorafenib tosylate inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib tosylate also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib tosylate weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib tosylate markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib tosylate potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib tosylate inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib tosylate significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib tosylate inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]
Kinase Assay Biochemical assays
Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research Cell lines MDA-MB-231, and HAoSMC
Concentrations Dissolved in DMSO, final concentrations ~10 μM
Incubation Time 72 hours
Method

Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.
Experimental Result Images Methods Biomarkers Images PMID
Western blot LC3-I / LC-3II / ATG5 p-STAT3 / STAT3/ Mcl-1 β-catenin / Survivin / Mcl-1 / PTMA pERK / ERK p-PKM2(Y105) / PMK2 / Caspase-9 RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204) Cyclin D1 23392173
Immunofluorescence p65 cytochrome c 22286758
Growth inhibition assay Cell viability 26039995
ELISA TGF-beta / CD206 Caspase-9 / Caspase-3 26158762
In Vivo
In vivo

Oral administration of Sorafenib tosylate (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib tosylatetreatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib tosylate treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2]
Animal Research Animal Models Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
Dosages ~60 mg/kg
Administration Orally once daily
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05068752 Recruiting Pancreas Cancer HonorHealth Research Institute|Bayer|Genentech Inc. October 28 2021 Phase 2
NCT04763408 Recruiting Carcinoma Hepatocellular Eisai Inc. April 9 2021 --
NCT04000737 Recruiting Advanced Hepatocellular Carcinoma Yiviva Inc. January 10 2020 Phase 2

Chemical lnformation & Solubility

Molecular Weight 637.03 Formula

C21H16ClF3N4O3.C7H8O3S
CAS No. 475207-59-1 SDF Download Sorafenib tosylate SDF
Smiles CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 127 mg/mL ( (199.36 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 0.01 mg/mL

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Sorafenib tosylate | Sorafenib tosylate supplier | purchase Sorafenib tosylate | Sorafenib tosylate cost | Sorafenib tosylate manufacturer | order Sorafenib tosylate | Sorafenib tosylate distributor